

Substitute for form 1449B/PTO

Complete if Known

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 2 of 6

Application Number	09/676,380
Filing Date	09/29/00
First Named Inventor	Maible
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	99-057

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>Ma</i>		REITER, JILL L. and MAIHLE, NITA J.; A 1.8 kb Alternative Transcript from the Human Epidermal Growth Factor Receptor Gene Encodes a Truncated Form of the Receptor; Journal; 4050-56 Nucleic Acids Research, 1996, Vol. 24, No. 20.	
		BARON, ANDRE T., et al; Monoclonal Antibodies Specific for Peptide Epitopes of the Epidermal Growth Factor Receptor's Extracellular Domain; Journal; HYBRIDOMA, Mary Ann Liebert, Inc., Mayo Clinic Foundation; Vol. 16, No. 3, 1997.	
		HAKJOO LEE and MAIHLE, NITA; Isolation and Characterization of Four Alternate c-erbB3 Transcripts expressed in Ovarian Cardinoma-derived Cell Lines and Normal Human Tissues; Oncogene (1998) 16, 3243-3252.	
		BARON, ANDRE T.; Serum sErbB1 and Epidermal Growth Factor Levels as Tumor Biomarkers in Women with Stage III or IV Epithelial Ovarian Cancer; Cancer Epidemiology, Biomarkers and Prevention, Vol. 8, 129-137, February 1999.	
		DOWNWALD, et al; article; Close Similarity of Epidermal Growth Factor Receptor and v-erbB oncogene protein sequences; NATURE, 307 (5951), 521-527 (1984).	
		ULLRICH, et al., article; NATURE, 309, 418 (1984).	
		COUSSENS, et al.; article; SCIENCE, 230, 1132-1139 (1985).	
		KRAUS et al.; article, PROC. NAT'L. ACAM. SCI. USA, 86, 9193 (1989).	
		PLOWMAN, et al; article, PROC. NAT'L. ACAM. SCI. USA, 87, 4905 (1991).	

Examiner Signature

Date

Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this



PTO/SB/08B (08-00)
 Approved for use through 10/31/2002. OMB 0651-0031
 U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT


(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

Application Number	09/676,380
Filing Date	09/29/00
First Named Inventor	Maible
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	99-057

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		MAIHLE, <i>et al</i> ; article; PROC NAT'L ACAM. SCI, 88, 1825 (1991).	
		ILEKIS, <i>et al</i> ; article; MOL. REPROD. DEVEL., 41, 149 (1995).	
		MERLINO, <i>et al</i> ; article; MOL. CELL. BIOL., 5, 1722 (1985).	
		HUNTS, <i>et al</i> ; CELL MOL. GENET., 11, 477 (1988).	
		PETCH <i>et al</i> ; MOL. CELL. BIOL., 10, 2973 (1990).	
		McKENZIE; article; BIOCHEM, BIOPHYS. ACTA, 1072, 193 (1991).	
		BRANDT-RAUF; article; MUTAT. RES., 333, 203 (1995).	
		MORI <i>et al</i> ; article; JPN. J. CANCER RES., 81, 489 (1990).	
		MEDEN <i>et al</i> ; article, ANTICANCER RES., 17, 757 (1997).	
		HAYES <i>et al</i> ; article; BREAST CANCER TREAT., 14, 135 (1993).	
		LEITZEL <i>et al</i> ; article; J. CLIN. ONCOL., 13, 1129 (1995).	
		YAMANCHI, <i>et al</i> ; article; J. CLIN. ONCOL., 15, 2518 (1997).	
		PARTANEN <i>et al</i> ; article; J. OCCUP. MED., 36, 1324 (1994).	
	PARTANEN <i>et al</i> ; article; INT. J. ONCOL., 4, 1025 (1995).		
	WITTERS <i>et al</i> ; article; CLIN. CANCER RES., 1, 551 (1995).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.


Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this



PTO/SB/08B (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 6

Complete if Known

Application Number	09/676,380
Filing Date	09/29/00
First Named Inventor	Maible
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	99-057

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ILEKIS, J.V., <i>et al</i> ; article; Expression of a Truncated Epidermal Growth Factor Receptor-like Protein (TEGFR) in Ovarian Cancer; GYNECOL. ONCOL. 65: 36-41 (1997).	
		XU <i>et al</i> ; article; PROC. NAT'L ACAD. SCI., 81, 7308 (1984).	
		SALOMEN <i>et al</i> ; article; CRIT. REV. ONCOL. HEMATOL., 19, 183 (1995).	
		KING <i>et al</i> ; article; SCIENCE, 229, 974 (1985).	
		HENDLER <i>et al</i> ; article; PROC. AM. SOC. CLIN. ONCOL., 8, 223 (1989).	
		VEALE <i>et al</i> ; article; CANCER RES., 49, 1313 (1989)	
		SCHLEGEL <i>et al</i> ; article; INT. J. CANCER, 56, 72 (1994).	
		NEAL, <i>et al</i> ; article; CANCER, 65, 1619 (1990).	
		MELLON <i>et al</i> ; article; J. UROL., 153, 919 (1995).	
		BERCHUCK <i>et al</i> ; article; AM. J. OBSTET. GYNECOL., 164, 669 (1991).	
		SCAMBIA <i>et al</i> ; article; J. CLIN. ONCOL., 10, 529 (1992).	
		SAMBROOK <i>et al</i> ; article; MOLECULAR CLONING: A Laboratory Manual, Cold Spring Harbor, NY (1989).	
		LAWN <i>et al</i> ; article; NUCLEIC ACIDS RES., 9, 6103 (1981).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**


(use as many sheets as necessary)


Sheet 5 of 6

Complete if Known

Application Number	09/676,380
Filing Date	09/29/00
First Named Inventor	Maihle
Group Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	99-057

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials ²	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOEDDEL <i>et al.</i> ; article; NUCLEIC ACIDS RES., 8, 4057 (1980).	
		ADELMAN, <i>et al.</i> ; article; DNA, 2, 183 (1983).	
		CREA, <i>et al.</i> ; article; PROC. NAT'L ACAD. SCI., 75, 5765 (1978)	
		VIERA <i>et al.</i> ; article; METH. ENZYMOL., 153, 3 (1987).	
		STEWART <i>et al.</i> , Solid Phase Peptide Synthesis, W.H. Freeman Co., San Francisco (1969)	
		MERRIFIELD, J. Am. Chem. Soc., 85, 2149 (1963)	
		MEIENHOFER, "Hormonal Proteins and Peptides," ed.	
		FLICKINGER <i>et al.</i> , Mol. Cell. Biol., 12, 883 (1992)	
		CHEN <i>et al.</i> , Nature, 32, 820 (1987)	
		AUSUBEL <i>et al.</i> , Curren Protocols in Molecular Biology, John Wiley & Sons, NY (1994)	
		MAIHLE <i>et al.</i> , Mol. Cell. Biol., 8, 4868 (1988)	
		WATERFIELD <i>et al.</i> , J. Cell. Biochem., 20, 149 (1989)	
	BARON <i>et al.</i> , October 1, 1998, A sandwich type acridinium-linked immunosorbent assay (ALISA) detects "soluble" ErbB1 (sErbB1) analogs in normal human serum; <i>J. Immunol. Methods</i> , 219, 23-43		

Examiner
SignatureDate
Considered

306/03/00

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Approved for use through 10/31/2002. OMB 0651-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 14498/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	6	of	6
-------	---	----	---

Complete if Known

Application Number	09/676,380
Filing Date	09/29/00
First Named Inventor	Maible
Group Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	99-057

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.